BONE MARROW FAILURE SYNDROME 4
|
0.600 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Patients with positiveMYSM1expression showed poor survival compared with the MYSM1 negative group (P<0.001).Simultaneously, multivariate Cox regression analysis indicated thatMYSM1 expression in tumor cells was an independent factor for reduced overall survival in CRC patients (P<0.001).Additionally,MYSM1 in CRC SW480 cells was silenced by small interference RNA (siRNA) technology.
|
28498834 |
2017 |
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
29020094 |
2017 |
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
29020094 |
2017 |
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
28498834 |
2017 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
28498834 |
2017 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
29020094 |
2017 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We observed that MYSM1 were downregulated in CRPC compared to localized prostate tumors.
|
31761786 |
2019 |
Renal fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results are clearly indicating that, aspirin prevents renal fibrosis in diabetic animals through decreasing the expression of Mysm1, increasing the expression of H2AK119-Ub and thereby decreasing the protein expression of Set7, which is a novel mechanism.
|
29656179 |
2018 |
BONE MARROW FAILURE SYNDROME 4
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Bone marrow hypocellularity
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|
Bone marrow hypocellularity
|
0.400 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Pancytopenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations.
|
28115216 |
2017 |
Pancytopenia
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Immunologic Deficiency Syndromes
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Malar flattening
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Neurodevelopmental delay
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Eczema
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dry skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Low set ears
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Midface retrusion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Rhizomelia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dry Skin, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|